Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer
Authors:
- Niklas KrebsNKNiklas Krebs
- Lukas KleinLKLukas Klein
- Florian WegwitzFWFlorian Wegwitz
- Elisa EspinetEEElisa Espinet
- Hans Carlo MaurerHMHans Carlo Maurer
- Mengyu TuMTMengyu Tu
- Frederike PenzFPFrederike Penz
- Stefan KüfferSKStefan Küffer
- Xingbo XuXXXingbo Xu
- Hanibal BohnenbergerHBHanibal Bohnenberger
- Silke CameronSCSilke Cameron
- Marius BrunnerMBMarius Brunner
Open Access
- 22 August 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (16)
Abstract
Metastatic pancreatic cancer (PDAC) has a poor clinical outcome with a 5-year survival rate below 3%. Recent transcriptome profiling of PDAC biopsies has identified 2 clinically distinct subtypes — the “basal-like” (BL) subtype with poor prognosis and therapy resistance compared with the less aggressive and drug-susceptible “classical” (CLA) subtype. However, the mechanistic events and environmental factors that promote the BL subtype identity are not very clear. Using preclinical models, patient-derived xenografts, and FACS-sorted PDAC patient biopsies, we report here that the axon guidance receptor, roundabout guidance receptor 3 (ROBO3), promotes the BL metastatic program via a potentially unique AXL/IL-6/phosphorylated STAT3 (p-STAT3) regulatory axis. RNA-Seq identified a ROBO3-mediated BL-specific gene program, while tyrosine kinase profiling revealed AXL as the key mediator of the p-STAT3 activation. CRISPR/dCas9-based ROBO3 silencing disrupted the AXL/p-STAT3 signaling axis, thereby halting metastasis and enhancing therapy sensitivity. Transcriptome analysis of resected patient tumors revealed that AXL hi neoplastic cells associated with the inflammatory stromal program. Combining AXL inhibitor and chemotherapy substantially restored a CLA phenotypic state and reduced disease aggressiveness. Thus, we conclude that a ROBO3-driven hierarchical network determines the inflammatory and prometastatic programs in a specific PDAC subtype.Keywords
Funding Information
- Max-Eder Research grant of German Cancer Aid to SKS (70112999)
- Deutsche Forschungsgemeinschaft (SI 2639/1-1)
- Wilhelm-Sander-Stiftung (2021.159.1)
This publication has 60 references indexed in Scilit:
- Axon Guidance Factor SLIT2 Inhibits Neural Invasion and Metastasis in Pancreatic CancerCancer Research, 2014
- STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptorProceedings of the National Academy of Sciences, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal TransitionJournal of Biological Chemistry, 2012
- IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial–Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling PathwayMolecular Cancer Research, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyNature Medicine, 2011